Аннотация:We herein report two patients with endometrial carcinoma who were under medication with tamoxifen as adjuvant therapy for breast cancer. A 70-year-old woman presented with vaginal bleeding who had been given tamoxifen 20mg daily for 8 years prior to admission. Curettage biopsy of the uterine endometrium confirmed the diagnosis of endometrial carcinoma. After receiving a cycle of preoperative chemotherapy with CDDP, CPM and EPI (CEP), she underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Histologically, it was well differentiated adenocarcinoma in Stage Ib (G2). There is no evidence of malignancy 37 months later. Another patient, a 66-year-old woman, had been receiving tamoxifen 20mg daily for 5 months after surgery. Endometrial carcinoma was diagnosed after repeated cytology. She was treated by total abdominal hysterectomy with bilateral salpingo-oophorectomy. Histologically, it was adenosquamous carcinoma in Stage Ib (G1). Postoperatively, she received two cycles of CEP. There has been no evidence of malignancy 44 months after the operation. Since most tumors reported in patients treated with tamoxifen in the Western randomized studies are early good-grade endometrial carcinoma, it is speculated that periodic detection strategy of endometrial changes of the uterine corpus is not strictly recommended. However, the patients should be followed up immediately with gynecologic examinations if spotting or bleeding occurs like in our patients.
